Cargando…
Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
Autores principales: | Guillemette, Chantal, Rouleau, Michèle, Vanura, Katrina, Lévesque, Éric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553966/ https://www.ncbi.nlm.nih.gov/pubmed/32704176 http://dx.doi.org/10.1038/s41416-020-1006-4 |
Ejemplares similares
-
UGT2B17 modifies drug response in chronic lymphocytic leukaemia
por: Allain, Eric P., et al.
Publicado: (2020) -
Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Papamichos, Spyros I., et al.
Publicado: (2020) -
Inactivation of Prostaglandin E(2) as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia
por: Allain, Eric P., et al.
Publicado: (2019) -
A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome
por: Wagner, Antoine, et al.
Publicado: (2023) -
Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival
por: Nguyen Van Long, Flora, et al.
Publicado: (2023)